High Cytoplasmic and Membranous Versus Nuclear Talin-1 Expression Associated With Malignancy Potential and Poor Survival in Clear Cell Renal Cell Carcinoma
preprint
OA: closed
Abstract
Using bioinformatics analysis Talin-1 protein was indicated as a potential prognostic focal adhesion factor in renal cell carcinoma (RCC). We, therefore, examined its protein expression levels and prognostic significant of Talin-1 with clinical follow-up in total of 269 tissue specimens from three important subtypes of RCC and 30 adjacent normal samples using tissue microarrays (TMAs). Then, we used combined analysis with B7-H3 to confirm that Talin-1 may be related to metastasis. The results showed that high membranous and cytoplasmic expression of Talin-1 was significantly associated with advanced nucleolar grade ( P < 0.001 , all), microvascular invasion ( P = 0.007, P = 0.004 , respectively), histological tumor necrosis ( P = 0.020 , P = 0.018 ), and invasion to Gerota’s fascia ( P = 0.025 , P = 0.050 ) in ccRCC. In addition, high membranous and cytoplasmic expression of Talin-1 was associated with significantly poorer disease-specific survival ( P = 0.043, P = 0.024 , respectively) and progression- free survival ( P = 0.046, in cytoplasm). Moreover, increased cytoplasmic expression of Talin-1 High / B7-H3 High compared to the other phenotypes was associated with poor prognosis and progression of the disease in patients with distant metastasis. Collectively, these observations indicate that Talin-1 is an important molecule involved in the spread and progression of ccRCC when expressed particularly in cytoplasm and may serve as a novel prognostic biomarker in this subtype.
My notes (saved in your browser only)
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
Source provenance
- europepmc
- last seen: 2026-05-19T01:45:01.086888+00:00